Boathouse Capital Realizes BioPharm Investment
June 9, 2016
Boathouse Capital announced today that it has successfully exited its investment in BioPharm Communications, a leading communications agency that specializes in the development and multi-channel deployment of proprietary marketing programs for physicians and healthcare practitioners for pharmaceutical and biotechnology clients. The exit was the result of Omnicom Health Group’s strategic acquisition of BioPharm. Boathouse and CMS Mezzanine partnered with Southfield Capital, the majority owner on the recapitalization of BioPharm in 2012.
Headquartered in New Hope, PA, BioPharm serves the majority of the largest pharmaceutical companies in the world. The business helps brand teams at pharmaceutical and biotech companies execute customized marketing campaigns through a comprehensive portfolio of proprietary program offerings. BioPharm’s offering complements sales representative promotion with a more efficient and targeted means of communication that saves valuable face time for physicians.
During Boathouse’s four-year investment, BioPharm completed an acquisition and bolstered its management team with the hiring of several key executives. The increased sales team along with new product offerings helped the revenues increase substantially during the hold period.
Bill Dyer, General Partner at Boathouse Capital, said, “I’m truly thankful for the opportunity to have partnered with Jeff Persinger and Daniel Egeland, co-founders, and everyone else at BioPharm. The business exceeded all expectations and yielded a fantastic outcome to our investors.”
“My team and I greatly appreciate the support we received from Boathouse throughout our four-year partnership. We are extremely proud of the growth that we achieved and are eager to enter into the next chapter of our business alongside Omnicom,” said Jeff Persinger, President and CEO of BioPharm.